← Evidence library

BIB_387

Adjuvant BRAF/MEK targeted therapy in resected melanoma — two-trial landscape update: (1) COLUMBUS-AD primary analysis (EORTC-2139-MG, ASCO 2025 LBA9501): encorafenib+binimetinib vs placebo in Stage IIB/C BRAF V600E/K — TERMINATED EARLY (n=110 of planned 815); safety/feasibility primary endpoint only; descriptive 12-month RFS 86% vs 70%; trial is NOT a practice-changing efficacy result; ICI remains standard at Stage IIB/C. (2) COMBI-AD final 10-year results (Hauschild, NEJM June 2024, PMID 38899716): dabrafenib+trametinib adjuvant at Stage III BRAF V600+ — RFS HR 0.52 (95% CI 0.43–0.63); DMFS …

Evidence grade

A

Tier

1 (Columbus-AD: ASCO 2025 LBA9501, EORTC Phase III trial, peer-reviewed conferen

Cited by tasks

15, 17, 18

Identifiers

DOI:10.1200/JCO · PMID:38899716

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_387/findings.md (research corpus). This page is a short context summary — not individualised medical advice.